Last updated: September 25, 2026
NEXIUM 24HR is Haleon’s U.S. over-the-counter esomeprazole product for frequent heartburn. Its original prescription franchise generated substantial revenue for AstraZeneca, but the prescription patent cycle ended years ago. The current business is an established consumer-health brand competing against store brands, generic esomeprazole, omeprazole, lansoprazole and private-label acid reducers.
Haleon does not publicly disclose standalone NEXIUM 24HR revenue. Financial analysis therefore relies on Haleon’s broader respiratory and digestive-health reporting, company-level brand disclosures, FDA records, retail-market dynamics and the post-switch history of esomeprazole.
What is NEXIUM 24HR and who markets it?
NEXIUM 24HR contains esomeprazole magnesium, a proton-pump inhibitor, or PPI. The standard U.S. OTC product is a 20 mg delayed-release capsule indicated for adults and children aged 18 years and older to treat frequent heartburn, defined on the label as heartburn occurring two or more days per week.
Haleon markets the product in the United States. The brand originated with AstraZeneca’s prescription and OTC Nexium franchise. Pfizer acquired AstraZeneca’s U.S. rights to several consumer products, including OTC Nexium, in 2008. The consumer-health assets later moved through the Pfizer-GSK transaction and into Haleon when the consumer-health business was separated from GSK in 2022.[1][2]
| Item |
NEXIUM 24HR profile |
| Active ingredient |
Esomeprazole magnesium |
| U.S. dosage form |
Delayed-release oral capsule |
| Typical OTC strength |
20 mg |
| Therapeutic class |
Proton-pump inhibitor |
| U.S. indication |
Frequent heartburn |
| U.S. marketer |
Haleon |
| Original prescription innovator |
AstraZeneca |
| U.S. OTC switch |
2003 for Nexium 24HR predecessor products; current OTC franchise developed through subsequent approvals and labeling |
| Prescription status |
Generic competition established |
| Biosimilar exposure |
None |
The OTC product is separate commercially from prescription NEXIUM, even though both contain esomeprazole. Prescription NEXIUM historically included 20 mg and 40 mg strengths and additional indications, such as gastroesophageal reflux disease, erosive esophagitis and certain ulcer-related conditions. NEXIUM 24HR is positioned around consumer self-care and heartburn prevention.
How has the NEXIUM financial trajectory changed?
NEXIUM’s financial trajectory has three distinct phases: prescription blockbuster growth, patent-driven erosion and consumer-health stabilization.
Prescription blockbuster phase
Nexium became one of AstraZeneca’s largest products after its U.S. launch in 2001. It was marketed as the purified S-isomer of omeprazole, with a clinical and commercial positioning centered on acid suppression and gastrointestinal disorders. AstraZeneca reported multibillion-dollar global sales during the product’s peak period.[3]
The prescription business benefited from:
- High physician awareness
- Broad gastroesophageal reflux disease use
- A large installed patient base
- Premium branded pricing
- Expansion from symptomatic heartburn into prescription treatment of erosive and ulcer-related conditions
Patent erosion phase
The prescription product faced generic and authorized-generic competition after key U.S. patent protections expired or were successfully challenged. Teva launched generic esomeprazole in 2015 after resolving patent litigation with AstraZeneca, and additional generic competition followed.[4]
The entry of generic esomeprazole materially reduced branded prescription revenue. The commercial effect was amplified by pharmacy-benefit substitution, mandatory generic dispensing and payer pressure. The loss of prescription exclusivity did not eliminate the consumer brand, but it changed the revenue model from protected pharmaceutical pricing to mass-market OTC competition.
Consumer-health phase
Haleon’s NEXIUM business now depends on consumer demand, retailer distribution, brand recognition and pricing execution. The product competes in a mature category in which consumers can choose among:
- NEXIUM 24HR
- Generic esomeprazole
- Prilosec OTC and generic omeprazole
- Prevacid 24HR and generic lansoprazole
- H2 blockers such as famotidine
- Antacids and alginate-based products
- Retailer and pharmacy private-label products
Haleon reports NEXIUM as one of its power brands but does not provide a separate annual revenue figure for NEXIUM 24HR in its public annual reports. The absence of brand-level revenue disclosure prevents a precise standalone revenue trend. Haleon’s reported group performance indicates that the brand participates in a much larger digestive-health portfolio rather than operating as a separately reported pharmaceutical segment.[5]
What is the current market position of NEXIUM 24HR?
NEXIUM 24HR has strong brand equity but faces substantial price competition. The principal commercial advantage is consumer recognition of “Nexium” as a high-efficacy acid-reflux product. The principal weakness is ingredient-level substitution: shoppers can obtain esomeprazole or alternative PPIs at materially lower prices.
The brand’s market position depends on five variables:
- Shelf placement and retailer distribution.
- Advertising and consumer awareness.
- Promotional pricing and coupons.
- Perceived superiority over generic esomeprazole.
- The relative growth of PPIs versus H2 blockers and non-drug remedies.
OTC heartburn products have recurring demand, but the category is mature. Volume can rise with diagnosis rates, aging populations, obesity prevalence and self-treatment of reflux symptoms. Revenue growth is more difficult because retailers and consumers can trade down to private-label products.
Haleon can increase reported sales through price increases, pack-size changes and premium positioning, but unit volume may weaken when consumers become more price-sensitive. This makes NEXIUM 24HR a brand-management asset rather than a conventional high-margin, patent-protected pharmaceutical.
How does NEXIUM 24HR compare with Prilosec OTC and Prevacid 24HR?
| Brand |
Active ingredient |
Main competitive position |
Patent dependence today |
Primary risk |
| NEXIUM 24HR |
Esomeprazole |
Premium PPI brand with strong recognition |
Low |
Generic and private-label substitution |
| Prilosec OTC |
Omeprazole |
Established mass-market PPI |
Low |
Price competition and category maturity |
| Prevacid 24HR |
Lansoprazole |
Alternative branded PPI |
Low |
Lower differentiation |
| Generic esomeprazole |
Esomeprazole |
Same active ingredient at lower price |
None at product level |
Direct substitution |
| Famotidine products |
Famotidine |
Faster-acting H2-blocker alternative |
Low |
Consumer preference for rapid relief |
| Private-label PPIs |
Various |
Lowest-price option |
None |
Retailer promotion and shelf allocation |
NEXIUM 24HR benefits from ingredient recognition, but esomeprazole has limited practical differentiation for many OTC consumers. The product therefore competes on trust, packaging, advertising and perceived effectiveness rather than exclusivity.
Prilosec OTC remains a direct comparator because omeprazole and esomeprazole are chemically related and occupy similar treatment territory. Prevacid 24HR competes in the same once-daily PPI segment. Famotidine-based products compete differently by emphasizing rapid symptom relief rather than the longer-term acid suppression profile associated with PPIs.
What is the FDA regulatory status of NEXIUM 24HR?
NEXIUM 24HR is an FDA-authorized OTC drug product. Its regulatory foundation is the FDA-approved switch of esomeprazole from prescription to nonprescription use and the associated consumer labeling.
The OTC label directs consumers to take one capsule daily for 14 days and not to take more than one capsule per day unless instructed by a doctor. The label also warns that the product is not intended for immediate relief and that consumers should seek medical advice for persistent or recurring symptoms.[6]
The main regulatory risks are labeling compliance, manufacturing quality, pharmacovigilance and possible changes in FDA treatment of long-term PPI use. FDA scrutiny of OTC PPIs would affect the entire category, not only NEXIUM 24HR.
Is NEXIUM 24HR an OTC-monograph product?
NEXIUM 24HR is associated with an approved OTC drug application and product-specific labeling rather than relying solely on an ordinary monograph pathway. The product’s switch required FDA review of consumer comprehension, safety, use patterns and labeling.
This regulatory history gives Haleon control over the branded presentation, but it does not create modern pharmaceutical exclusivity comparable to a newly approved prescription drug.
What patents protect NEXIUM 24HR?
The commercial patent protection for NEXIUM 24HR is limited. The major patent value was associated with prescription esomeprazole, not the current OTC brand.
Historical U.S. patents associated with AstraZeneca’s esomeprazole and omeprazole franchise included patents covering the active compound, formulations, salts, pharmaceutical compositions and methods of treatment. Key patents cited in historical litigation and regulatory disputes included U.S. Patent Nos. 5,714,504, 5,877,192 and 6,369,085, although the scope and expiration dates differed by patent and claim.[4][7]
Those patents no longer provide a meaningful barrier to generic esomeprazole. The commercial protection available to NEXIUM 24HR now comes mainly from:
- The NEXIUM trademark
- Consumer recognition
- FDA-approved labeling
- Packaging and trade dress
- Distribution relationships
- Advertising claims supported by regulatory requirements
- Manufacturing and quality systems
Does NEXIUM 24HR have Orange Book protection?
The relevant prescription NEXIUM patents were historically listed in the FDA Orange Book. The existence of those historic listings did not prevent later generic esomeprazole entry.
The current commercial strength of NEXIUM 24HR should not be measured by Orange Book patent listings alone. OTC branded products can remain commercially important after patent expiry because their value resides in brand demand and retail execution. A generic manufacturer does not need to defeat a current patent estate to compete with the product.
When did Nexium lose prescription exclusivity?
Nexium lost meaningful U.S. prescription exclusivity after generic esomeprazole entered the market in 2015. The entry followed AstraZeneca’s settlement with Teva, which allowed Teva to market generic esomeprazole before the full expiry of certain asserted patent rights.[4]
| Milestone |
Approximate timing |
Commercial effect |
| Prescription Nexium U.S. launch |
2001 |
Creation of the branded franchise |
| OTC Nexium expansion |
2000s |
Shift into consumer self-care |
| Key prescription patent disputes |
2010-2014 |
Delayed or contested generic entry |
| Teva generic settlement and launch |
2015 |
Rapid prescription revenue erosion |
| Haleon separation |
2022 |
Current consumer-health ownership structure |
| Current period |
2020s |
Mature OTC brand with generic competition |
The prescription and OTC businesses should be analyzed separately. Generic prescription entry reduced pharmaceutical pricing power, while the OTC business retained a branded retail presence.
Are there Paragraph IV challenges to NEXIUM 24HR?
Paragraph IV challenges primarily targeted prescription generic esomeprazole, not the current OTC NEXIUM 24HR retail product. A Paragraph IV certification is a generic applicant’s assertion that a listed patent is invalid, unenforceable or not infringed.
Historical litigation involving generic esomeprazole included claims against manufacturers such as Teva and related generic applicants. Those disputes centered on prescription NEXIUM patents and generic approval timing. They did not create an ongoing exclusivity barrier for OTC NEXIUM 24HR.
The current generic-entry risk is therefore not a new Paragraph IV event. It is continuing substitution by generic esomeprazole and other acid-reducing products.
What formulation patents protect NEXIUM 24HR?
NEXIUM 24HR uses a delayed-release formulation designed to protect esomeprazole from degradation in the stomach and permit release in the intestine. The formulation technology is important to product quality, but comparable delayed-release esomeprazole products are already available.
Potential formulation protections historically covered matters such as:
- Enteric-coated dosage forms
- Pharmaceutical compositions
- Stabilization of acid-sensitive proton-pump inhibitors
- Granules, pellets or multiparticulate delivery systems
- Delayed-release capsules
The practical barrier is manufacturing know-how and regulatory compliance, not a strong current monopoly. Generic manufacturers have demonstrated the ability to produce and obtain approval for delayed-release esomeprazole products.
What manufacturing and intellectual-property barriers remain?
The remaining barriers are moderate for OTC brand competition and low for generic active-ingredient competition.
Haleon’s advantages include:
- Established supplier and quality networks
- Scale in procurement and distribution
- Retailer relationships
- Consumer advertising capability
- Brand recognition
- Experience managing FDA OTC labeling
Generic manufacturers face FDA quality requirements, bioequivalence or performance requirements, stability testing, packaging controls and supply-chain execution. Those requirements create operating costs but do not form a durable barrier comparable to patent exclusivity.
A competitor seeking to launch a new branded OTC PPI would face a different challenge: consumer acquisition costs and retailer access. The market is open legally but difficult commercially because established brands and private-label products occupy the same shelves.
Which companies are challenging NEXIUM 24HR commercially?
The main commercial challengers are generic manufacturers and consumer-health companies rather than originator pharmaceutical companies.
Relevant competitor groups include:
- Generic esomeprazole manufacturers such as Teva and other FDA-approved suppliers
- Private-label retailers selling esomeprazole, omeprazole or lansoprazole
- Owners of Prilosec OTC and Prevacid 24HR
- Manufacturers of famotidine and antacid products
- Digital pharmacies and online retailers using lower prices to shift consumers toward generics
The competitive threat is fragmented. No single competitor must defeat Haleon’s brand. Retailers can gradually increase private-label shelf space, while generic suppliers can capture price-sensitive consumers.
What is the revenue exposure for Haleon?
NEXIUM is commercially relevant to Haleon but is not publicly reported as a standalone revenue line. Haleon’s financial statements aggregate revenue by geographic region, category and brand portfolio. The company identifies power brands, but product-level revenue and profit figures are generally unavailable.[5]
The financial exposure has three dimensions:
| Exposure |
Direction |
Explanation |
| Brand sales |
Positive |
NEXIUM contributes to digestive-health revenue |
| Price realization |
Mixed |
Premium pricing supports revenue but increases trade-down risk |
| Patent loss |
Largely historical |
Prescription patent erosion occurred before Haleon ownership |
| Volume growth |
Limited |
Mature PPI category with broad substitution |
| Margin |
Potentially attractive |
Consumer brands can generate strong margins, but advertising and retailer fees reduce contribution |
| Litigation risk |
Lower than prescription era |
Current risk centers on consumer, regulatory and quality issues |
NEXIUM 24HR is unlikely to recreate the financial profile of prescription Nexium. Its value is a recurring consumer franchise with defensible brand equity, not a protected pharmaceutical cash flow.
What generic launch scenarios exist for NEXIUM 24HR?
Three scenarios define the current market.
Base case: gradual branded erosion
NEXIUM 24HR maintains broad distribution and premium pricing, while generic and private-label products capture incremental unit share. Haleon uses advertising, promotions and packaging to preserve value share. Revenue is stable to modestly declining in nominal terms, depending on pricing and category growth.
Downside case: accelerated trade-down
Retailers expand private-label esomeprazole placement, inflation increases consumer price sensitivity and online channels make generic substitution easier. Unit and value share decline faster. Haleon responds with promotions, which can protect volume but compress margins.
Upside case: category expansion
Growth in self-treatment, stronger heartburn incidence and effective brand advertising increase the PPI category. NEXIUM 24HR retains premium positioning and converts consumers from less effective or less familiar alternatives. The upside remains constrained by low product differentiation and mature category economics.
What litigation and settlement agreements affect NEXIUM 24HR?
The most significant litigation was historical prescription patent litigation involving AstraZeneca and generic esomeprazole applicants. Settlement agreements enabled generic entry before the expiration of all asserted patent terms, reducing the period of practical market exclusivity.[4]
There is no comparable current patent litigation barrier publicly defining the NEXIUM 24HR business. Future disputes are more likely to involve:
- Trademark infringement
- False or misleading advertising
- Product liability
- Manufacturing quality
- Consumer labeling
- Retail or distribution practices
The patent-litigation risk profile is therefore substantially lower than it was during the prescription Nexium lifecycle.
How strong is the NEXIUM 24HR patent estate?
The patent estate is weak as a current exclusivity asset and strong only as a historical record of pharmaceutical innovation and litigation.
| Dimension |
Assessment |
| Active-ingredient exclusivity |
Low |
| Prescription patent protection |
Expired or commercially overcome |
| Formulation protection |
Limited practical effect |
| Trademark protection |
Stronger than patent protection |
| OTC regulatory position |
Established |
| Manufacturing know-how |
Moderate |
| Retail and brand moat |
Moderate |
| Generic-entry barrier |
Low |
The brand can remain profitable without patent exclusivity because consumers purchase branded OTC products for convenience, trust and perceived performance. That commercial moat is durable but vulnerable to retailer private labels and price compression.
What are the geographic coverage and international considerations?
NEXIUM and esomeprazole have broad international presence, but product ownership, regulatory status and branding vary by country. Some markets classify esomeprazole products as prescription-only, while others permit nonprescription sale under local conditions.
The United States is particularly important because OTC switching created a large consumer-health opportunity. International revenue is affected by:
- National reimbursement systems
- Prescription and OTC classification
- Local generic penetration
- Pharmacy versus grocery distribution
- Brand ownership and licensing arrangements
- National advertising restrictions
- Currency movements
Haleon’s global distribution provides scale, but it does not create uniform pricing or exclusivity. In many markets, local generic companies can compete at substantially lower prices.
Key Takeaways
- NEXIUM 24HR is a Haleon OTC esomeprazole brand for frequent heartburn.
- Its prescription predecessor lost meaningful U.S. exclusivity when generic esomeprazole entered in 2015.
- Current value comes primarily from brand equity, retail distribution, labeling and manufacturing scale.
- The FDA-approved OTC product has no meaningful modern patent moat against generic esomeprazole.
- Haleon does not disclose standalone NEXIUM 24HR revenue, preventing a precise product-level financial forecast.
- The principal commercial risks are private-label substitution, generic pricing, retailer bargaining power and category maturity.
- Paragraph IV litigation is primarily historical and relates to prescription Nexium patents.
- Biosimilars do not create a risk because esomeprazole is a small-molecule drug, not a biologic.
- NEXIUM 24HR remains commercially defensible as a consumer brand but not as a patent-protected pharmaceutical franchise.
FAQs About NEXIUM 24HR
Is NEXIUM 24HR the same as prescription Nexium?
Both contain esomeprazole, but prescription Nexium and NEXIUM 24HR differ in approved indications, labeling, strengths, distribution and regulatory status.
Can generic esomeprazole replace NEXIUM 24HR?
Generic esomeprazole is a direct commercial substitute, subject to product-specific labeling, dosage and regulatory requirements. Consumers commonly trade between branded and generic versions based on price and availability.
Does Haleon disclose NEXIUM 24HR annual sales?
No. Haleon reports broader category and brand-portfolio information but does not generally disclose standalone NEXIUM 24HR revenue or profit.
Does NEXIUM 24HR face biosimilar competition?
No. Esomeprazole is a chemically synthesized small-molecule drug. Its competitors are generic drugs and alternative acid-reducing products, not biosimilars.
Is NEXIUM 24HR still protected by AstraZeneca patents?
The key prescription patent protections associated with Nexium have expired or have been commercially overcome. Current NEXIUM 24HR protection depends mainly on the Haleon trademark, regulatory compliance, brand equity and retail execution.
References
- AstraZeneca. (2008). AstraZeneca and Pfizer announce agreement for U.S. rights to OTC Nexium and other consumer products.
- Haleon plc. (2022). Haleon annual report and financial statements 2022.
- AstraZeneca plc. (2005). Annual report and Form 20-F 2004.
- United States Court of Appeals for the Federal Circuit. (2014). AstraZeneca AB v. Apotex Corp., 782 F.3d 1324.
- Haleon plc. (2024). Annual report and financial statements 2023.
- U.S. Food and Drug Administration. (2024). NEXIUM 24HR drug facts label.
- U.S. Patent and Trademark Office. (2024). Patent Center records for U.S. Patent Nos. 5,714,504; 5,877,192; and 6,369,085.
